Liver Transplant Success Rate in India: How It Compares to Global Standards (2026)
When a family member needs a liver transplant, the first question is rarely about cost or location. It is: will they survive?
Success rates are the most emotionally weighted piece of information in liver transplant decision-making, and they are frequently misunderstood. Numbers are cited without context, compared across mismatched time periods, or drawn from databases that measure different patient populations. This guide gives you a clear, evidence-grounded picture of liver transplant outcomes in India — and how they honestly compare to the USA, UK, Germany, South Korea, and Singapore.
The short answer: India's top liver transplant centres report 1-year patient survival rates of 88–93%, comparable to leading centres in the USA and Europe. The living donor liver transplant (LDLT) programme, in which India leads the world in volume, achieves 1-year survival rates of 90–95% at the best centres. Cost is 70–85% lower than Western countries for equivalent outcomes.
Understanding Liver Transplant Success Rates
Before comparing numbers, it helps to understand what "success rate" means — and what it does not.
Graft survival refers to whether the transplanted liver continues to function. Patient survival refers to whether the person is alive. These are related but different: a patient can survive a graft failure by receiving a second transplant.
Most published outcome data cites 1-year patient survival and 5-year patient survival as the primary benchmarks. These are measured from the date of transplant.
Success rates also vary significantly based on:
- Indication for transplant: Acute liver failure has a higher perioperative risk than chronic liver disease. Hepatocellular carcinoma (liver cancer) has lower 5-year survival than cirrhosis from other causes.
- MELD score at transplant: The Model for End-Stage Liver Disease score measures disease severity. Higher MELD scores indicate sicker patients and historically correlate with slightly lower early survival rates, though India's ICU capabilities are strong.
- Donor type: Living donor (LDLT) vs. deceased donor (DDLT) — India is predominantly LDLT, which has different outcome characteristics.
- Volume of the centre: Centres performing more transplants have better outcomes across all international literature.
India's Overall Liver Transplant Survival Rates
India's leading liver transplant centres publish outcomes data that places them in the first tier globally:
- 1-year patient survival: 88–93% at high-volume Indian centres
- 5-year patient survival: 75–82% at leading programmes
- Living donor liver transplant (LDLT) 1-year survival: 90–95% at top centres
- Paediatric liver transplant 1-year survival: 85–92%
These figures are drawn from published data and outcome reports from centres including Medanta (Gurugram), Apollo Hospitals (Delhi, Chennai, Hyderabad), Fortis Memorial Research Institute, and Global Hospitals (Mumbai, Chennai).
It is important to note that these figures represent high-volume reference centres — not an average of all hospitals in India that perform liver transplantation. As with any country, outcomes at lower-volume or less-specialised programmes are lower. The guidance for international patients is consistent: choose a centre performing at least 100 liver transplants per year, and preferably one of the programmes performing 200 or more.
How India Compares Globally
The following table compares 1-year and 5-year patient survival rates for liver transplantation across major medical destinations. Data is drawn from national transplant registries and published centre-level data where available.
| Country / Region | 1-Year Survival | 5-Year Survival | Programme Type |
|---|---|---|---|
| USA (UNOS national average) | 89–91% | 74–77% | Predominantly DDLT |
| UK (NHSBT national data) | 87–91% | 72–76% | Predominantly DDLT |
| Germany (DSO registry) | 85–89% | 70–74% | Predominantly DDLT |
| South Korea (top centres) | 87–91% | 78–84% | LDLT-heavy |
| Singapore (top centres) | 85–90% | 73–79% | Mixed |
| India (top centres) | 88–93% | 75–82% | LDLT-heavy |
India's numbers are within the range of leading Western countries and are superior to several European national averages. The comparison is most meaningful at the level of specific high-volume centres rather than national averages — India's top 5–6 centres perform at or above the median of the world's best programmes.
A note on LDLT vs DDLT outcomes: Living donor liver transplantation (where a healthy family member donates a portion of their liver) typically shows slightly better early outcomes than deceased donor transplantation because the organ quality is higher and the transplant is scheduled rather than urgent. India's dominance in LDLT — driven by the relative scarcity of deceased donors in the country — means that Indian centres have accumulated extraordinary LDLT expertise over the past two decades. This benefits international patients who travel with a compatible living donor.
Why India's Success Rates Are High
India's strong outcomes are not accidental. Several structural factors drive them.
Volume and Specialisation
Volume is the single best-validated predictor of transplant outcomes in peer-reviewed literature. Medanta The Medicity performed over 500 liver transplants in 2024, making it one of the highest-volume programmes globally. Apollo Hospitals collectively across campuses performs several hundred more. These numbers matter: surgical teams at this volume have encountered — and solved — rare complications that lower-volume programmes see once every few years.
Living Donor Expertise
India has developed the world's most refined living donor liver transplant techniques over the past two decades, driven by necessity. The proportion of right-lobe LDLT, left-lobe LDLT, and extended left-lobe LDLT performed in India exceeds that of any other country. This technical specialisation translates into better outcomes for donor safety and recipient survival.
ICU and Perioperative Care
Liver transplant outcomes are heavily influenced by the quality of perioperative ICU management — the hours and days immediately after surgery. India's leading transplant centres invest heavily in transplant hepatology nurses, specialised transplant ICUs, and 24-hour specialist coverage. The concentration of experienced ICU nurses and hepatologists at reference centres like Medanta, Apollo, and Global Hospitals is comparable to top US academic medical centres.
Technology and Techniques
India's high-volume transplant centres are early adopters of advanced techniques: laparoscopic donor hepatectomy (key-hole surgery for the donor), MARS (Molecular Adsorbent Recirculating System) for acute liver failure, and split liver techniques that allow one deceased donor liver to be shared between two recipients. These advances improve outcomes and expand the range of patients who can be successfully transplanted.
India's Top Liver Transplant Centres and Their Outcomes
Medanta – The Medicity (Gurugram)
Medanta's Institute of Liver Transplantation and Regenerative Medicine is the reference programme in India. Led by surgeons trained in the world's top centres, it consistently reports 1-year survival rates of 90–93% for LDLT recipients. The programme performs the largest volume of liver transplants in the country and publishes its outcomes data in peer-reviewed journals. For international patients seeking the highest-volume programme with the most comprehensive outcomes transparency, Medanta is the benchmark.
Apollo Hospitals (Delhi, Chennai, Hyderabad)
Apollo's liver transplant programmes across campuses collectively perform several hundred transplants annually. The Delhi and Chennai campuses in particular have long track records in both LDLT and DDLT. Apollo publishes outcomes data through its Institute of Liver Diseases and Transplantation. The programme's strength includes its hepatology team — liver transplant outcomes depend as much on pre- and post-transplant medical management as on surgery itself.
Fortis Memorial Research Institute (Gurugram)
Fortis FMRI has a long-standing liver transplant programme with strong outcomes data, particularly in paediatric liver transplantation. The programme is notable for its multidisciplinary tumour board approach to hepatocellular carcinoma cases, which improves selection and post-transplant oncology management.
Global Hospitals (Mumbai and Chennai)
Global Hospitals' liver transplant programme in Mumbai is one of the city's strongest, with published 1-year survival data in the 88–92% range. The Chennai campus is similarly capable. For patients arriving from West Africa, the Mumbai campus offers a geographically convenient choice with strong outcomes.
ILBS – Institute of Liver and Biliary Sciences (Delhi)
ILBS is a government-sector specialist institution dedicated exclusively to liver disease. It performs a substantial volume of liver transplants and offers pricing significantly below private hospitals — making it relevant for cost-sensitive international patients. Waiting times for deceased donor organs are longer, but the LDLT programme is active and outcomes are strong. The concentration of hepatology expertise in a single-specialty institution is a meaningful advantage.
Living Donor vs Deceased Donor: Does It Affect Success Rates?
For international patients, this is a practically important question.
LDLT (Living Donor Liver Transplant): The donor is typically a healthy family member aged 18–55 with a compatible blood group. A portion of their liver (usually the right lobe for adult recipients) is surgically removed and transplanted. The donor's liver regenerates to near-full function within 6–8 weeks.
- Advantages for the recipient: Scheduled surgery (not emergency), higher organ quality, shorter cold ischaemia time
- 1-year survival at Indian top centres: 90–95%
- Donor risk: Well-managed at top centres; serious complication rate for donors at high-volume Indian programmes is under 1%
DDLT (Deceased Donor Liver Transplant): Organ from a brain-dead donor. Less common in India due to lower deceased donor rates, and international patients have very limited access to deceased donor organs due to government regulations that prioritise Indian citizens.
- 1-year survival at Indian top centres: 85–91%
- Availability for international patients: Very limited; most international patients proceed with LDLT
For the vast majority of international patients travelling to India for liver transplantation, LDLT with a family member donor is the route. If you are planning this route, have your potential donor evaluated (blood group, general health, cross-sectional imaging) before travelling so that evaluation can be completed quickly on arrival.
Paediatric Liver Transplant Success in India
Children with biliary atresia, metabolic liver disease, and acute liver failure represent a significant proportion of liver transplant patients at India's top programmes. Paediatric liver transplant outcomes at dedicated programmes are strong:
- 1-year patient survival in paediatric LDLT: 85–92% at top centres
- 5-year survival: 75–83%
Medanta, Apollo, and Fortis are the strongest paediatric liver transplant programmes in India, with experience in infant transplantation (recipients weighing under 5 kg). For families from African countries where paediatric liver transplant is unavailable, India represents one of the most accessible and affordable destinations globally for this complex procedure.
What Affects Your Individual Success Rate?
Population-level statistics apply to groups. Your individual success depends on factors specific to you or your family member:
Disease severity: Patients with a MELD score below 15 at the time of transplant have consistently better outcomes than those transplanted at very high MELD scores (above 30). Early referral — before disease becomes critical — significantly improves outcomes. This is one of the strongest arguments for seeking evaluation early rather than waiting for a crisis.
Cause of liver failure: Viral hepatitis B cirrhosis and autoimmune liver disease tend to have better post-transplant survival than alcoholic cirrhosis (requiring proven sobriety) or certain metabolic conditions. Hepatocellular carcinoma transplant outcomes depend heavily on tumour size and number — cases meeting the Milan Criteria have 5-year survivals of 70–78%.
Donor quality in LDLT: A young, healthy donor in the 25–40 age range typically provides better graft quality than an older donor with fatty liver disease. The transplant team evaluates donors carefully — a rejected donor evaluation protects both donor and recipient.
Post-transplant medication compliance: Immunosuppressant medications (tacrolimus, mycophenolate) must be taken precisely and long-term. Non-compliance is a leading cause of late graft failure globally. This aspect of success is entirely within the patient's control.
Questions to Ask Your Transplant Surgeon
Before committing to a liver transplant programme in India, ask these specific questions:
- How many liver transplants did your programme perform last year?
- What is your published 1-year patient survival rate for LDLT?
- What is your donor morbidity rate for right-lobe LDLT?
- How many transplants has my specific surgeon performed independently, and what are their individual outcomes?
- What does your post-transplant follow-up protocol include for international patients returning home?
- Do you have a relationship with hepatologists in my home country for ongoing immunosuppression management?
A programme confident in its outcomes will answer these questions directly. Vague or evasive answers are a warning sign.
What the Numbers Cannot Tell You
Success statistics measure whether people survive and whether grafts function. They do not capture several things that matter enormously to patients and families:
- The quality of communication during the pre-transplant evaluation
- The compassion and cultural sensitivity of nursing and ward staff
- The clarity of discharge planning and post-transplant education
- The responsiveness of the international patient team when problems arise after you return home
India's best liver transplant programmes are strong on the measurable outcomes. Before choosing, seek out accounts from patients who have gone through these programmes — not just statistics from the hospital's marketing materials. Authentic patient experiences tell you things that survival data cannot.
For a family weighing a liver transplant in India, the evidence is clear: the country's leading centres deliver outcomes that match the global standard at a fraction of the cost, with particular expertise in living donor transplantation that may be relevant to your family's situation.
